Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection: A Randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 313, Issue 17, 2015, Pages 1719-1727

  Gerding, Dale N ^a,b   Meyer, Thomas ^c   Lee, Christine ^d   Cohen, Stuart H ^e   Murthy, Uma K ^f   Poirier, Andre ^g   Van Schooneveld, Trevor C ^h   Pardi, Darrell S ⁱ   Ramos, Antonio ^j   Barron, Michelle A ^k   Chen, Hongzi ^l   Villano, Stephen ^l  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c INDIANA UNIVERSITY HEALTH   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^g UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k UNIVERSITY OF COLORADO   (United States)

^l SHIRE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; METRONIDAZOLE; PLACEBO; UNCLASSIFIED DRUG; VANCOMYCIN; VP 20621;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIUM DETECTION; CANADA; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EUROPE; FECES ANALYSIS; FEMALE; FEMUR FRACTURE; FLATULENCE; HEADACHE; HUMAN; INFECTION PREVENTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; SEPSIS; TREATMENT DURATION; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; SECONDARY PREVENTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; DOUBLE-BLIND METHOD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SECONDARY PREVENTION; SPORES, BACTERIAL;

EID: 84929148131     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.3725     Document Type: Article

References (20)

1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-834.
2. Magill SS, Edwards JR, Bamberg W, et al Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198-1208.
3. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3):197-205.
4. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197(3):435-438.
5. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.
6. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012;30(29):4307-4309.
7. Gerding DN. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov Med. 2012;13(68):75-83.
8. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998;351(9103):633-636.
9. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother. 2012;56(10):5224-5229.
10. Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol. 1985;19(3):339-350.
11. Seal D, Borriello SP, Barclay F, Welch A, Piper M, Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol. 1987;6(1):51-53.
12. Wilson KH, Sheagren JN. Antagonism of toxigenic Clostridium difficile by nontoxigenic C difficile. J Infect Dis. 1983;147(4):733-736.
13. Merrigan MM, Sambol SP, Johnson S, Gerding DN. Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis. 2003;188(12):1922-1927.
14. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis. 2002;186(12):1781-1789.
15. Clabots CR, Johnson S, Bettin KM, et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol. 1993;31(7):1870-1875.
16. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008;47(1):56-62.
17. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med. 1992;117(4):297-302.
18. Johnson S, Louie TJ, Gerding DN, et al Polymer Alternative for CDI Treatment Investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345-354.
19. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302-307.
20. Brouwer MS, Roberts AP, Hussain H, Williams RJ, Allan E, Mullany P. Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat Commun. 2013;4:2601.